<DOC>
	<DOCNO>NCT01108809</DOCNO>
	<brief_summary>The study design evaluate effect treatment Micardis/MicardisPlus blood pressure ability reduce different indicate cardiovascular risk score . The study also evaluate current antihypertensive treatment pattern daily practice among patient population increase cardiovascular risk .</brief_summary>
	<brief_title>Evaluation Effect Telmisartan Blood Pressure Control High Risk Patients</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Inclusion criterion : diagnosis essential arterial hypertension ( BP &gt; 140/90 mm HG BP &gt; 130/80 mm Hg diabetic patient ) least one additional cardiovascular risk factor and/or know single multiple end organ damage and/or previous cardiovascular disease Exclusion criterion : hypersensitivity active substance excipients ACE inhibitor angiotensin receptor blocker ( ARB ) available local market , prescribe SPC pregnancy lactation diseases involve biliary obstruction severe liver impairment severe hypertension malignant hypertension secondary hypertension patient age 18 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>